PRFX
PRFX
PRF Technologies Ltd.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $1.18M | $-1.16M | 0% | $-13.75 | $-1.09M |
| Q1-2025 | $0 | $1.18M ▲ | $-1.16M ▼ | 0% | $-13.75 ▲ | $-1.09M ▼ |
| Q4-2024 | $0 | $881.5K | $-885K | 0% | $-15 | $-877.5K |
| Q3-2024 | $0 | $881.5K ▼ | $-885K ▲ | 0% | $-15 ▲ | $-877.5K ▲ |
| Q2-2024 | $0 | $7.34M | $-7.31M | 0% | $-1.26K | $-7.34M |
What's going well?
The company is keeping its spending steady and hasn't taken on debt or unusual charges. R&D spending shows they may be working on new products.
What's concerning?
No revenue for two straight quarters and high ongoing losses are a major red flag. Heavy overhead with no sales means the company is burning cash with no sign of a turnaround.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $4.14M ▲ | $12M ▲ | $2.71M ▼ | $8.54M ▲ |
| Q2-2025 | $3.48M | $11.16M | $2.72M | $8.44M |
| Q1-2025 | $3.48M ▼ | $11.16M ▲ | $2.72M ▲ | $8.44M ▲ |
| Q4-2024 | $4.26M | $4.53M | $2.7M | $1.82M |
| Q3-2024 | $4.26M | $4.53M | $2.7M | $1.82M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-1.16M | $-991K | $-25K | $623.5K | $0 | $-991K |
| Q1-2025 | $-1.16M ▼ | $-991K ▲ | $-25K ▼ | $623.5K ▼ | $0 | $-991K ▲ |
| Q4-2024 | $-885K | $-1.99M | $-500 | $2.73M | $0 ▲ | $-1.99M |
| Q3-2024 | $-885K ▲ | $-1.99M ▲ | $-500 ▲ | $2.73M ▼ | $-2.79M ▼ | $-1.99M ▲ |
| Q2-2024 | $-7.31M | $-4.95M | $-5K | $3.41M | $-1.54M | $-4.95M |
What's strong about this company's cash flow?
There are no strengths in the current cash flow - the business is not generating cash and has no cash cushion.
What are the cash flow concerns?
The company is burning real cash every quarter, has no cash left, and relies entirely on outside funding to survive. Without new money, it cannot keep operating.
5-Year Trend Analysis
A comprehensive look at PRF Technologies Ltd.'s financial evolution and strategic trajectory over the past five years.
Key strengths include a strong orientation toward innovation in two high-potential areas—non-opioid pain management and renewable energy analytics—supported by proprietary technologies and early strategic partnerships. The balance sheet shows low financial leverage and a net cash position, providing some flexibility to pursue the R&D agenda. R&D investment is substantial and ongoing, which, while painful for near-term profits, demonstrates a clear commitment to building differentiated products rather than competing solely on price. The dual business model also offers some diversification of opportunity, with success in either major segment having the potential to reshape the company’s profile.
Major risks stem from the company’s very weak current financial performance—minimal revenue, large recurring losses, and substantial negative cash flow—which create ongoing dependence on external financing and the possibility of future dilution. Clinical, regulatory, and commercialization risks around PRF-110 and OcuRing-K are high and binary: setbacks can materially impair the value of the drug portfolio. In energy analytics, PRFX must compete against much larger and better-funded players while still proving the scalability and stickiness of DeepSolar. Managing two very different businesses simultaneously adds operational complexity, and the heavy reliance on intangible assets and historical accumulated losses underscore how much of the company’s value is still unproven.
The outlook is highly uncertain and strongly event-driven. In the near to medium term, financial results are likely to remain weak unless there is a step-change in revenue from successful commercialization of either the pharmaceutical assets or the DeepSolar platform. Key future developments include resolving PRF-110 trial issues, advancing OcuRing-K into later stages, securing and defending critical patents, and converting pilot projects and partnerships in solar analytics into recurring, scaled revenue streams. If these milestones progress favorably, PRFX’s profile could shift meaningfully over time, but until then it should be viewed as a small, development-stage company with significant execution, funding, and competitive risks balanced against the possibility of substantial upside from successful innovation.
About PRF Technologies Ltd.
https://prf-tech.comPRF Technologies Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $1.18M | $-1.16M | 0% | $-13.75 | $-1.09M |
| Q1-2025 | $0 | $1.18M ▲ | $-1.16M ▼ | 0% | $-13.75 ▲ | $-1.09M ▼ |
| Q4-2024 | $0 | $881.5K | $-885K | 0% | $-15 | $-877.5K |
| Q3-2024 | $0 | $881.5K ▼ | $-885K ▲ | 0% | $-15 ▲ | $-877.5K ▲ |
| Q2-2024 | $0 | $7.34M | $-7.31M | 0% | $-1.26K | $-7.34M |
What's going well?
The company is keeping its spending steady and hasn't taken on debt or unusual charges. R&D spending shows they may be working on new products.
What's concerning?
No revenue for two straight quarters and high ongoing losses are a major red flag. Heavy overhead with no sales means the company is burning cash with no sign of a turnaround.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $4.14M ▲ | $12M ▲ | $2.71M ▼ | $8.54M ▲ |
| Q2-2025 | $3.48M | $11.16M | $2.72M | $8.44M |
| Q1-2025 | $3.48M ▼ | $11.16M ▲ | $2.72M ▲ | $8.44M ▲ |
| Q4-2024 | $4.26M | $4.53M | $2.7M | $1.82M |
| Q3-2024 | $4.26M | $4.53M | $2.7M | $1.82M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-1.16M | $-991K | $-25K | $623.5K | $0 | $-991K |
| Q1-2025 | $-1.16M ▼ | $-991K ▲ | $-25K ▼ | $623.5K ▼ | $0 | $-991K ▲ |
| Q4-2024 | $-885K | $-1.99M | $-500 | $2.73M | $0 ▲ | $-1.99M |
| Q3-2024 | $-885K ▲ | $-1.99M ▲ | $-500 ▲ | $2.73M ▼ | $-2.79M ▼ | $-1.99M ▲ |
| Q2-2024 | $-7.31M | $-4.95M | $-5K | $3.41M | $-1.54M | $-4.95M |
What's strong about this company's cash flow?
There are no strengths in the current cash flow - the business is not generating cash and has no cash cushion.
What are the cash flow concerns?
The company is burning real cash every quarter, has no cash left, and relies entirely on outside funding to survive. Without new money, it cannot keep operating.
5-Year Trend Analysis
A comprehensive look at PRF Technologies Ltd.'s financial evolution and strategic trajectory over the past five years.
Key strengths include a strong orientation toward innovation in two high-potential areas—non-opioid pain management and renewable energy analytics—supported by proprietary technologies and early strategic partnerships. The balance sheet shows low financial leverage and a net cash position, providing some flexibility to pursue the R&D agenda. R&D investment is substantial and ongoing, which, while painful for near-term profits, demonstrates a clear commitment to building differentiated products rather than competing solely on price. The dual business model also offers some diversification of opportunity, with success in either major segment having the potential to reshape the company’s profile.
Major risks stem from the company’s very weak current financial performance—minimal revenue, large recurring losses, and substantial negative cash flow—which create ongoing dependence on external financing and the possibility of future dilution. Clinical, regulatory, and commercialization risks around PRF-110 and OcuRing-K are high and binary: setbacks can materially impair the value of the drug portfolio. In energy analytics, PRFX must compete against much larger and better-funded players while still proving the scalability and stickiness of DeepSolar. Managing two very different businesses simultaneously adds operational complexity, and the heavy reliance on intangible assets and historical accumulated losses underscore how much of the company’s value is still unproven.
The outlook is highly uncertain and strongly event-driven. In the near to medium term, financial results are likely to remain weak unless there is a step-change in revenue from successful commercialization of either the pharmaceutical assets or the DeepSolar platform. Key future developments include resolving PRF-110 trial issues, advancing OcuRing-K into later stages, securing and defending critical patents, and converting pilot projects and partnerships in solar analytics into recurring, scaled revenue streams. If these milestones progress favorably, PRFX’s profile could shift meaningfully over time, but until then it should be viewed as a small, development-stage company with significant execution, funding, and competitive risks balanced against the possibility of substantial upside from successful innovation.
CEO
Efraim Cohen-Arazi
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2026-02-06 | Reverse | 1:5 |
| 2026-02-05 | Reverse | 1:5 |
Ratings Snapshot
Rating : C